Septerna, Inc. (SEPN) stock
SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30195% above fair value
$42.60+0.74 (+1.77%)
Close on Nov 13, 2026Market cap $1.99BP/E –Yield –
Septerna EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Septerna's EPS for the twelve months ending Sep 30, 2026 was -$1.29. For fiscal 2025 it was -$1.10.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.10 | – |
| FY2024 | Dec 31, 2024 | -$7.26 | -2603.4% |
| FY2023 | Dec 31, 2023 | $0.29 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.57 | -416.7% |
| Q2 FY2026 | Jun 30, 2026 | -$0.29 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.19 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.24 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.18 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.56 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.49 | -104.4% |
| Q3 FY2024 | Sep 30, 2024 | -$8.40 | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.03 | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.35 | – |
| Q4 FY2023 | Dec 31, 2023 | $11.18 | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.45 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?